StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird
November 23, 2016 10:40 AM
Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Trader Talk
Next Articles
Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success
November 25, 2016 8:52 AM
Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness
November 23, 2016 9:48 AM
Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital
November 23, 2016 9:27 AM
Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
November 23, 2016 9:24 AM
Sola Failures Appears 'Near-Perfect' for Biogen (BIIB) - Stifel
November 23, 2016 8:40 AM
Forward Pharma (FWP): Reiterating Buy Ahead Of Next Week's Litigation - Leerink
November 23, 2016 8:36 AM
Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink
November 23, 2016 7:57 AM
Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's
November 23, 2016 7:05 AM
Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure
November 23, 2016 6:52 AM
